All In Biotech

Drug Trial Radar · NCT01345630

Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1

A Multicenter, Randomized, Double-Blind, Comparative Trial Of Maraviroc + Darunavir/Ritonavir Versus Emtricitabine/Tenofovir + Darunavir/Ritonavir For The Treatment Of Antiretroviral-Naive Hiv-Infected Patients With Ccr5-Tropic Hiv-1

Last checked: Nov 19, 2026Latest source record: Jan 14, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 813 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

813

Actual

Start

Sep 2011

Primary completion

Aug 2013

Study completion Jan 2014

Sponsor

Lead sponsor
ViiV HealthcareGSK (GSK)
Sponsor type
Industry
Collaborators
Pfizer
First posted
May 2, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess whether maraviroc administered once daily is non-inferior to emtricitabine/tenofovir also administered once daily each in combination with darunavir/ritonavir in the treatment of antiretroviral-naive patients as evaluated at Week 48 of treatment.

Conditions

  • HIV-1

Interventions

  • MaravirocDrug

    Maraviroc tablet 150 mg once daily for 96 weeks.

  • Emtricitabine/tenofovirDrug

    Emtricitabine/tenofovir tablet 200/300 mg once daily for 96 weeks.

  • darunavir/ritonavir 800/100 mgDrug

    darunavir/ritonavir 800/100 mg

  • placebo for emtricitabine/tenofovirDrug

    placebo for emtricitabine/tenofovir

  • placebo for maravirocDrug

    placebo for maraviroc

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Plasma HIV-1 RNA <50 Copies/mL.Time frame: Week 48

Locations

177 sites in 19 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham - 1917 Research Clinic

    Birmingham, Alabama

  • Health Services Center

    Hobson City, Alabama

  • Kaiser Permanente

    Hayward, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • Dr. Anthony Mills, MD, Inc.

    Los Angeles, California

  • Orange Coast Medical Group

    Newport Beach, California

  • Desert Oasis Healthcare Medical Group

    Palm Springs, California

  • University of California Davis Research

    Sacramento, California

  • TICON I Research Clinic (DEXA Scan only)

    Sacramento, California

  • Kaiser Hospital Sacramento

    Sacramento, California

  • Synarc Inc.

    San Francisco, California

  • Investigational Drugs Pharmacy

    San Francisco, California

  • Kaiser Permanente - Clinical Trials Unit

    San Francisco, California

  • Kaiser Permanente Santa Clara

    Santa Clara, California

  • Kaiser Permanente

    Union City, California

  • University of Colorado Denver - University of Colorado Hospital

    Aurora, Colorado

  • Kaiser Permanente of Colorado

    Denver, Colorado

  • Yale - New Haven Hospital Nathan Smith Clinic

    New Haven, Connecticut

  • Yale University

    New Haven, Connecticut

  • Circle CARE Center

    Norwalk, Connecticut

  • Capital Medical Associates, PC

    Washington D.C., District of Columbia

  • George Washington University Medical Faculty Associates

    Washington D.C., District of Columbia

  • Broward Health - Comprehensive Care Center

    Fort Lauderdale, Florida

  • Broward General Medical Center

    Fort Lauderdale, Florida

  • The Kinder Medical Group

    Miami, Florida

  • UMHC/Sylvester Comprehensive Cancer Center

    Miami, Florida

  • University of Miami AIDS Clinical Research Unit

    Miami, Florida

  • University of Miami

    Miami, Florida

  • Community AIDS Resource Inc dba Care Resource

    Miami, Florida

  • Miami Research Associates

    Miami, Florida

  • Wohlfeiler, Piperato and Associates, LLC

    Miami Beach, Florida

  • Infectious Diseases Associates of Northwest Florida, PA

    Pensacola, Florida

  • St. Joseph's Hospital Diagnostic Center

    Tampa, Florida

  • University of South Florida Health-HIV Clinical Research Unit

    Tampa, Florida

  • Infectious Disease Research Institute, Inc.

    Tampa, Florida

  • Osteoporosis Care Center

    Tampa, Florida

  • Quest Diagnostic Laboratory

    Tampa, Florida

  • Rowan Tree Medical, PA

    Wilton Manors, Florida

  • AIDS Research Consortium of Atlanta

    Atlanta, Georgia

  • DeKalb Medical Diagnostic Breast Center

    Decatur, Georgia

Showing 40 of 177 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.